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Abstract
Background: (Pro)renin receptor (PRR) is a new component of the renin–angiotensin system and regulates renin
activity in vitro. Within the kidney, PRR is highly expressed in the renal medulla where its expression is induced by
angiotensin II infusion. The objective of the present study was to test a potential role of renal medullary PRR during
angiotensin II-induced hypertension.
Methods: A rat AngII infusion model (100 ng/kg/min) combined with renal intramedullary infusion of PRO20, a
specific inhibitor of PRR, was builded. And the intravenous PRO20 infusion serve as control. Mean arterial pressure
was recorded by radiotelemetry for one week. Further anaylsis of kidney injury, inflammation, biochemical indices
and protein localization were perrformed in vivo or in vitro.
Results: Radiotelemetry demonstrated that AngII infusion elevated the mean arteria pressure from 108 ± 5.8 to
164.7 ± 6.2 mmHg. Mean arterial pressure decreased to 128.6 ± 5.8 mmHg (P < 0.05) after intramedullary infusion of
PRO20, but was only modestly affected by intravenous PRO20 infusion. Indices of kidney injury, including
proteinuria, glomerulosclerosis, and interstitial fibrosis, inflammation, and increased renal medullary and urinary
renin activity following angiotensin II infusion were all remarkably attenuated by intramedullary PRO20 infusion.
Following one week of angiotensin II infusion, increased PRR immunoreactivity was found in vascular smooth
muscle cells. In cultured rat vascular smooth muscle cells, angiotensin II induced parallel increases in soluble PRR
and renin activity, and the latter was significantly reduced by PRO20.
Conclusion: Renal medullary PRR mediates angiotensin II-induced hypertension, likely by amplifying the local renin
response.
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Background
The renin–angiotensin system (RAS) is one of the most
important regulatory systems for the control of extracel-
lular volume and blood pressure (BP). Over-activation
of the RAS plays an essential role in the pathogenesis
of hypertension as evidenced by the wide use of
angiotensin-converting enzyme (ACE) inhibitors and
AT1-receptor antagonists for the management of human
hypertension [1–3]. In humans and animals, activation
of the RAS due to renal artery stenosis leads to profound
hypertension and cardiovascular morbidity [4]. Angio-
tensin II (AngII), the major effector hormone of the
RAS, when given at a pressor dose, readily induces
hypertension [5]. However, despite intensive investiga-
tion, the mechanism of AngII-induced hypertension is
still incompletely understood. Although diverse mecha-
nisms have been proposed, increasing evidence suggests
involvement of the local RAS found in a variety of
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tissues, including the brain, heart, adrenal gland, vascu-
lature, and kidney [6, 7]. Over the past decade, there has
been a paradigm change in our understanding of the po-
tential role of the local versus systemic RAS in the
pathogenesis of hypertension. In particular, mounting
evidence is available to support an essential role of the
intrarenal RAS in AngII-induced hypertension.
(Pro)renin receptor (PRR) was cloned as a specific re-
ceptor for prorenin and renin by Nguyen et al. in 2002
[8]. It is a 350-amino-acid protein containing a single
transmembrane domain [9]. A soluble form of PRR
(sPRR), that is, the N-terminal domain fragment, is gen-
erated by intracellular cleavage by furin and secreted in
plasma [10]. The carboxyterminal tail has previously
been purified from chromaffin granules as an 8–9-kDa
accessory protein (M8-9) of the vacuolar-type H
+-ATPase and designated ATP6AP2 [11]. In vitro evi-
dence demonstrates that prorenin bound to PRR has in-
creased catalytic activity, thus mediating local AngII
formation [8, 12]. In light of its ubiquitous expression in
a variety of tissues, PRR is postulated to function as a
regulator of tissue renin activity [13]. However, there is
no convincing in vivo evidence to prove the renin-
regulatory function of PRR. Apart from prorenin or
renin activation, activation of PRR by (pro)renin stimu-
lates a variety of signal transduction pathways such as
mitogen-activated protein kinase [14] and Wnt-β-
catenin pathways [15], independent of AngII [14, 15].
Within the kidney, high levels of PRR immunoreactivity
have been detected in intercalated cells of the collecting
duct (CD) [16, 17] as well as vascular smooth muscle
cells (VSMC) [8]. Previous studies from us and others
have shown that PRR expression in the kidney, particu-
larly in the renal medulla, increases during AngII-
induced hypertension, dependent of the COX-2/EP4
pathway [16, 18–20]. The present study tested the func-




Male Sprague-Dawley rats (220–250 g, Charles River La-
boratories, Wilmington, MA, USA) were cage-housed
and maintained in a temperature-controlled room with a
12:12-h light–dark cycle, with free access to tap water
and standard rat chow for 14 days. The animal protocols
were approved by the Animal Care and Use Committees
at Sun Yat-sen University and University of Utah. The
rats underwent uninephrectomy with or without bilat-
eral adrenalectomy and were instrumented with radio-
telemetric devices. After one week’s recovery from the
surgery, a second surgery was performed to place a sub-
cutaneous osmotic mini-pump delivering vehicle or
AngII at 100 ng/kg/min. In this surgery, the kidney was
exposed from the flank region and a catheter was placed
in the renal medulla, approximately 4.0 mm underneath
the surface, and secured using Vetbond glue; the other
end of the catheter was connected to an osmotic mini-
pump delivering vehicle or PRO20 at 120 μg/kg/d. A
separate group of rats received intravenous infusion of
PRO20 via the jugular vein and served as a control. Ad-
renalectomized rats were given dexamethasone at 1 mg/
ml in their drinking water starting 2 days prior to adre-
nalectomy until the end of the experiment. The radio-
telemetric device was implanted via catheterization of
the carotid artery and was turned on for 4 h per day
from 5:00 p.m. to 9:00 p.m. The data from the rats with
incorrectly positioned intramedullary infusion catheters
detected at sacrifice were excluded from the final analysis.
Biochemical analysis of renin
Renin activity in plasma, urine, tissue homogenates, and
cell culture medium was determined under the native
condition by measurement of AngI generation using
enzyme-linked immunosorbent assay (ELISA). Aldoster-
one concentrations in plasma, urine, and cell culture
medium were measured using a commercial ELISA
kit (Cat#:10004377, Cayman Chemical, Ann Arbor,
Michigan, USA).
Enzyme immunoassay
To detect urinary or medium prorenin/renin, sPRR, we
used the following commercially available enzyme im-
munoassay kits according to the manufacturer’s instruc-
tions: prorenin/renin (Molecular Innovations, Novi, MI,
USA) and sPRR (IBL, Toronto, Canada).
Renal histology
Under anesthesia, kidneys were harvested and fixed with
10 % paraformaldehyde. The tissues were subsequently
embedded in paraffin and 4-μm sections were cut and
stained with periodic acid–Schiff. Renal pathologies in-
cluding glomerulosclerosis and interstitial fibrosis were
scored on a 1–4 scale as previously described [21] (the
higher the number, the more severe the injury).
Quantitative reverse transcriptase polymerase chain
reaction
For Quantitative reverse transcription polymerase chain
reaction (qRT-PCR), total RNA isolation and reverse
transcription were performed as previously described
[22]. Oligonucleotides were designed using Primer3
software (available at http://bioinfo.ut.ee/primer3-0.4.0/).
Primers for TNF-α were 5′- CCACGTCGTAGCAAACC
ACCAAG-3′ (sense) and 5′- CAGGTACATGGGCTCA
TACC-3′ (antisense); primers for IL-18 were 5′-TGGA-
GACTTGGAATCAGACC-3′ (sense) and 5′-GGCAAGC-
TAGAAAGTGTCCT-3′ (antisense); primers for GAPDH




The tissues were fixed in 10 % neutral buffered formalin for
24 h and then embedded in paraffin. After deparaffinization,
thin sections (4 μm) were processed for double-labeling
with immunofluorescence. The slides were blocked in 1 %
bovine serum albumin for 1 h and were then incubated with
primary antibody at 4 °C overnight. After washing off the
primary antibody, sections were incubated for 1 h at
room temperature with Donkey anti-goat-IgG- fluorescein
isothiocyanate (1:75, sc-2024, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or donkey anti-rabbit IgG-
tetramethylrhodamine (1:100, A31572, Life Technologies,
Grand Island, NY, USA). Rabbit anti-PRR antibody was
raised against residues 335–350 in the C terminus (Cat#:
ab40790, Abcam, Cambridge, MA, USA). Mouse anti-α-
smooth muscle actin (α-SMA) antibody was purchased
from Sigma (Cat#: F3777, Sigma, St Louis, MO, USA).
Cell culture
Rat aorta smooth muscle cell line (VSMC) was purchased
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Fig. 1 Effect of intramedullary (pro)renin receptor (PRR) inhibition on angiotensin II (AngII)-induced hypertension in rats. Uninephrectomized male
Sprague-Dawley rats were divided into the following three groups: (1) AngII, (2) AngII + intramedullary PRO20 infusion (IM PRO20), and (3) AngII +
intravenous PRO20 infusion (IV PRO20). AngII was subcutaneously infused at 100 ng/kg/min via an osmotic mini-pump. IM PRO20 (PRO20 at 120
μg/kg/d) was performed via a catheter chronically implanted in the renal medulla. To control the spillover, IV PRO (PRO20 at 120 μg/kg/d) was
performed via catheterization of the jugular vein. Telemetry was performed to monitor mean arterial pressure (MAP) and it was turned on 4 h per
day from 5:00 p.m. to 9:00 p.m. for 7 days. a Radiotelemetry monitoring of MAP. #P < 0.01 versus intravenous PRO20; *P < 0.05 versus AngII alone.
b Cardiac hypertrophy. Heart weight is expressed as percentage of body weight. Control (CTR), N = 6; AngII + Vehicle, N = 9; AngII + IM PRO20, N
= 8; AngII + IV PRO20, N = 6. Data are mean ± standard error
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grown in a six-well plate. After the cell monolayers
reached 95 % confluence, the VSMCs were pretreated with
PRO20 (1.5 μM) for 1 h, followed by AngII treatment at
100 nM for 24 h. After the treatment, the medium was
collected for enzyme assays or renin assays.
Statistical analysis
Data is summarized as means ± standard error (SE). All
data points were included in the statistical analyses.
Sample sizes were determined on the basis of similar
previous studies or pilot experiments. Statistical analysis
for animal and cell cultures experiments was performed
using analysis of variance with the Bonferroni test for
multiple comparisons or by paired or unpaired Student’s
t-test for two comparisons. A P-value below 0.05 was
considered statistically significant.
Results
Pharmacological investigation of renal medullary function
of PRR
PRO20 is a newly developed 21-amino-acid PRR decoy
peptide that interrupts the binding of prorenin to PRR
with high potency and specificity [23]. To probe the
functional role of renal medullary PRR, we employed an
intramedullary infusion technique that allows site-
specific delivery of an agent to the renal medulla [24].
To this end, a catheter was chronically implanted in the
renal medulla of nephrectomized rats to achieve site-
specific delivery of PRO20, and intravenous infusion of
this peptide via the jugular vein served as a control for
spillover. Radiotelemetry was used to monitor daily
mean arterial pressure (MAP). One-week AngII infusion
induced immediate and sustained increases in MAP,
from 108 ± 5.8 (day 0) to 164.7 ± 6.2 mmHg (day 7)
(Fig. 1a). Intramedullary PRO20 infusion (IM PRO20)
remarkably attenuated AngII-induced hypertension and
lowered the MAP to 128.6 ± 5.8 mmHg. However, intra-
venous PRO20 infusion (IV PRO20) was much less ef-
fective than IM PRO20 in lowering MAP (Fig. 1a).
Consistent with the BP data, AngII-induced cardiac
hypertrophy was blunted by IM PRO20 but not IV
PRO20 (Fig. 1b).
Following AngII infusion, the uninephrectomized rats
developed severe kidney injury as evidenced by increased
proteinuria (Fig. 2a) and renal histological changes,
including glomerulosclerosis and interstitial fibrosis
B














































CTR AngII AngII + IM PRO20
Fig. 2 Effect of intramedullary (pro)renin receptor (PRR) inhibition on angiotensin II (AngII)-induced kidney injury in rats. a Measurement of urinary
protein excretion using Coomassie blue. b Representative micrographs of periodic acid–Schiff staining of kidney sections. c Renal injury scores
from semi-quantitative analysis of renal pathologies. N = 6–14 per group. Data are mean ± standard error. CTR control, IM PRO20 intramedullary
PRO20 infusion, IV PRO20 intravenous PRO20 infusion
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(Fig. 2b, c). These indices of kidney injury were all atten-
uated by IM PRO20 (Fig. 2a–c). An inflammatory re-
sponse is a well known important feature of AngII-
induced hypertension [25, 26]. Therefore, we examined
renal expression of inflammatory markers such as TNF-
α and IL-18 using qRT-PCR. Both cytokines were ele-
vated by AngII infusion and were blunted by IM PRO
(Fig. 3a, b). PRO20 treatment via intramedullary or
intravenous infusion was not associated with any notice-
able toxicity.
AngII infusion induces a local renin response in the
renal medulla but suppresses systemic renin activity [16,
18, 27–29]. We hypothesized that PRR may be required
to enhance the renal medullary renin response to AngII.
As expected, following AngII infusion, renin activity was
suppressed in plasma and the renal cortex but enhanced
in the inner medulla and urine, and the latter response
was blunted by IM PRO20 (Fig. 4a–d). ELISA showed
that prorenin/renin content in the inner medulla was el-
evated by AngII infusion but was unaffected by IM
PRO20 (Fig. 5a) and the same result was obtained by
qRT-PCR of renin mRNA (Fig.5b), supporting the con-
cept that PRR primarily regulates local renin activity but
not renin expression. Of note, the ELISA kit was unable
to differentiate between prorenin and renin.
Regulation and function of vascular PRR
Immunostaining revealed the strongest signal of PRR in
the vascular smooth muscle in the kidney (Fig. 6a). This
signal was specific because it was completely eliminated
by the immunizing peptide (Fig. 6a). The vascular label-
ing of PRR appeared weaker in the heart as compared to
that in the kidney (Fig. 6a). AngII infusion enhanced the
















































Fig. 3 Effect of intramedullary (pro)renin receptor (PRR) inhibition on renal inner medullary expression of cytokines during angiotensin II (AngII)-
induced hypertension in rats. a, b The expression of tumor necrosis factor alpha (TNF-α) and interleukin 18 (IL-18) in the inner medulla of control
(CTR), AngII, and AngII + intramedullary PRO20-infused (AngII + IM RPO20) rats was determined by quantitative reverse transcriptase polymerase
chain reaction, which is normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH). N = 6 per group. Data are mean ± standard error
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labeling was co-localized with α-SMA labeling (Fig. 6b).
In cultured rat VSMC, exposure to 100 nM AngII for 24
h induced a marked increase in medium prorenin/renin
and sPRR, both being assessed by ELISA (Fig. 7a). In
parallel, renin activity was increased, as reflected by
measuring AngI generation, and was blunted by PRO20
(Fig. 7b).
Discussion
The importance of the RAS in the pathogenesis of hu-
man hypertension is highlighted by the wide use of ACE
inhibitors and angiotensin receptor blockers as first-line
antihypertensive therapies [1–3]. However, despite inten-
sive investigation, the mechanism of AngII-induced
hypertension is still incompletely understood. We used a
pharmacological approach to investigate the functional
role of renal medullary PRR during AngII-induced
hypertension. PRO20 is a newly developed, highly spe-
cific PRR decoy inhibitor that interrupts the binding of
prorenin to PRR [30]. The inhibitor was directly deliv-
ered to the rat renal medulla to evaluate the contribu-
tion of renal medullary PRR to AngII-induced
hypertension. The result showed that renal delivery of
PRO20 almost completely abolished AngII-induced
hypertension, contrasting with a relatively modest BP-
lowering effect of IV PRO20. The difference in the ef-
fects of local versus systemic delivery of PRO20 reflects
the contribution of renal medullary PRR.
Although abundant in vitro evidence demonstrates
that PRR binds renin and prorenin to increase their cata-
lytic activity [8, 12, 31–33], solid in vivo evidence to sup-
port PRR as a renin regulator is still lacking. In fact,
increasing skepticism has surrounded the renin-
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Fig. 4 Effect of intramedullary (pro)renin receptor (PRR) inhibition on renin levels in angiotensin II (AngII)-infused rats. Plasma, urine, and renal
tissues from control (CTR), AngII, and AngII + intramedullary PRO20-infused (AngII + IM RPO20) rats were assayed for renin activity by measurement
of AngI generation. a Plasma renin activity. b Renal cortical renin activity. c Renal inner medullary renin activity. d Urinary renin activity. N = 5–6
per group. Data are means ± standard error
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of human PRR in rats resulted in proteinuria and ne-
phropathy but did not elevate BP or renal AngII levels
[34, 35]. The lack of viable PRR null mice and an effect-
ive PRR inhibitor has made it difficult to convincingly
prove PRR as a key player in the RAS [36]. In the
present study, renal medullary and urinary renin activity
was activated following AngII infusion, whereas plasma
and renal cortical renin activity was suppressed,
highlighting differences between systemic versus intrare-
nal renin systems as documented by previous studies
[16, 18, 27]. AngII-induced increases in renal inner me-
dullary and urinary renin activity were remarkably sup-
pressed by IM PRO20. These results represent strong in
vivo evidence for a role of PRR in the regulation of local
renin activity during AngII-induced hypertension.
We assessed the direct role of PRR in the regulation of
renin activity in cultured VSMC following AngII
treatment. Exposure of VSMC to AngII induced a sig-
nificant increase in medium renin activity, suggesting a
positive feedback regulation of local RAS by AngII in
the vasculature contrasting to the negative feedback
regulation at the juxtaglomerular apparatus. This finding
is in agreement with the appreciated role of the local
RAS in the vascular remodeling in animal models of bal-
loon injury [37], spontaneously hypertensive rats [38],
and one-kidney, one-clip-induced and two-kidney, one-
clip-induced hypertension [39, 40]. We found that the
AngII-induced local renin response in VSMC was atten-
uated by PRO20, indicating involvement of PRR. Like-
wise, PRR plays an important role in amplifying the
vascular renin response to AngII. We suspect the PRR-
dependent activation of the local RAS may participate in
the regulation of vascular function or remodeling during





Fig. 5 Effect of intramedullary (pro)renin receptor (PRR) inhibition on renal inner medullary prorenin/renin expression in angiotensin II (AngII)-
infused rats. The expression of prorenin/renin in the inner medulla was determined by using enzyme-linked immunosorbent assay (ELISA) and
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) determined in Control (CTR), AngII, or AngII + intramedullary PRO20-infused
(AngII + IM RPO20) rats. a ELISA detection of prorenin/renin content. b qRT-PCR detection of renin mRNA expression. N = 5–6 per group. Data are
means ± standard error
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with the significant role of PRR in determining the in-
tegrity of VSMC [41]. Besides VSMC, the CD is another
important site for increased renal PRR expression in this
hypertension model, as shown previously [16, 18], and
likely plays a contributory role as well. Similarly, renin
secretion from the CD cells is also stimulated by AngII
[27] and this stimulation is likely mediated by PRR. The
relative importance of vascular versus tubular PRR
PRR - kidney PRR+peptide IgG PRR - heart
PRR 100 α-SMA MergePRR
B
A
a b c d
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Fig. 6 Immunostaining analysis of renal (pro)renin receptor (PRR) expression during angiotensin II (AngII)-induced hypertension. a Validation of
specificity of the labeling. (a) Immunostaining of PRR antibody in kidney; (b) Immunostaining in the kidney in the presence of the immune PRR
peptide (Cat#ab41522, Abcam); (c) Immunostaining of the kidney with rabbit IgG protein only; (d) Immunostaining of PRR in the heart. b Co-
labeling with anti-PRR antibody and anti-α-SMA antibody in control group (e–h) and AngII group (i–l). The kidney section was stained with anti-
PRR antibody and anti-α-SMA antibody (e–g; i–k). The merged images are shown in (h) and (l). (e) and (i): 100× magnification; (f–h) and (j–i): 400×
magnification. Shown are representatives of three to six animals per group
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remains elusive and awaits genetic validation in the fu-
ture studies. There is an intriguing possibility that PRR-
dependent regulation of the local renin response may
coordinate the functions of the vasculature and the CD.
Such coordination can be mediated by releasing sPRR,
which acts in an autocrine or paracrine fashion.
Irrespective of the underlying mechanism, the present
study has characterized PRO20 as a novel therapeutic
approach for hypertension and kidney injury. However,
the well-recognized developmental role of PRR may
imply a safety concern with this approach. In both low
vertebrates and mammals, PRR plays an essential role in
embryogenesis, likely via activation of the Wnt/β-catenin
pathway [15, 36]. In particular, deletion of PRR in mice
in a conventional or conditional manner leads to a lethal
phenotype [36, 42]. However, to our surprise, there was
no noticeable toxicity associated with PRO20 in the
current experimental model. In agreement with this ob-
servation, inhibition of the Wnt/β-catenin pathway ex-
hibits antifibrotic and protective effects in animal
models of diverse fibrotic diseases in the kidney [43–45],
skin [46], and lung [47] with a generally optimal safety
profile. It is possible that the developmental pathway
may be selectively activated in some disease processes
and may represent an attractive therapeutic target.
Conclusion
The present study employed a newly developed PRR-
decoy peptide, PRO20, coupled with an intramedullary
infusion technique to investigate the functional role of
renal medullary PRR during AngII-induced hyperten-
sion. Not only did we demonstrate a remarkable BP-
lowering effect of intramedullary PRR antagonism, but
we also underscored a novel mechanism of this
phenomenon involving PRR-dependent activation of the
local renin response. We for the first time demonstrate
the renin regulatory function of PRR in vivo and in vitro
and report PRO20 as a novel therapeutic agent for
hypertension and chronic kidney disease.
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Fig. 7 Effect of angiotensin II (AngII) on prorenin/renin content, soluble (pro)renin receptor (sPRR) content and renin activity in rat vascular
smooth muscle cells (VSMCs). The cells were exposed to 100 nM AngII for 24 h and medium prorenin/renin content (a) and sPRR content (b) was
analyzed by enzyme-linked immunosorbent assay. Medium renin activity (c) was analyzed by measurement of AngI generation in the absence of
substrate. N = 12 per group. Data are means ± standard error. CTR control
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PRO20: intramedullary PRO20 infusion; IV PRO20: intravenous PRO20 infusion;
MAP: mean arterial pressure; PRR: (pro)renin receptor; qRT-PCR: quantitative
reverse transcriptase polymerase chain reaction; RAS: renin-angiotensin
system; sPRR: soluble form of PRR; VSMC: vascular smooth muscle cells.
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